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OBJECTIVES We performed a meta-analysis of randomized trials comparing coronary artery bypass graft surgery
(CABG) with percutaneous transluminal coronary angioplasty (PTCA) for the treatment of
coronary artery disease, incorporating new trials and examining long-term outcomes.
BACKGROUND Previous meta-analyses of trials comparing CABG with PTCA have reported short- and
intermediate-term outcomes, but since then longer term follow-up and newer trials have been
published.
METHODS We performed a meta-analysis of 13 randomized trials on 7,964 patients comparing PTCA
with CABG.
RESULTS We found a 1.9% absolute survival advantage favoring CABG over PTCA for all trials at five
years (p  0.02), but no significant advantage at one, three, or eight years. In subgroup
analysis of multivessel disease, CABG provided significant survival advantage at both five and
eight years. Patients randomized to PTCA had more repeat revascularizations at all time
points (risk difference [RD] 24% to 38%, p  0.001); with stents, this RD was reduced to
15% at one and three years. Stents also resulted in a significant decrease in nonfatal
myocardial infarction at three years when compared with CABG. For diabetic patients,
CABG provided a significant survival advantage over PTCA at 4 years but not at 6.5 years.
CONCLUSIONS Our results suggest that, when compared with PTCA, CABG is associated with a lower
five-year mortality, less angina, and fewer revascularization procedures. For patients with
multivessel disease, CABG provided a survival advantage at five to eight years, and for
diabetics, a survival advantage at four years. The addition of stents reduced the need for repeat
revascularization by about half. (J Am Coll Cardiol 2003;41:1293–304) © 2003 by the
American College of Cardiology Foundation
An estimated 12.4 million adults in the U.S. are living with
coronary heart disease, as manifest by angina or a history of
myocardial infarction (MI). In 1999, there were an esti-
mated 571,000 coronary artery bypass graft (CABG) sur-
geries and more than one million inpatient percutaneous
transluminal coronary angioplasty (PTCA) procedures (1).
Recent guidelines for the management of coronary artery
disease include specific recommendations regarding revas-
cularization strategy based on extensive literature review,
qualitative analysis, consensus of expert opinion, and meta-
analysis (2–4).
Previous meta-analyses compared one- to three-year
outcomes of randomized trials comparing PTCA with
CABG and found no significant difference in rates of death
or MI (5,6). Since then, longer follow-up, additional ran-
domized trials, and newer technologies such as stents have
become available. Also, questions regarding benefits in
subgroups such as diabetic patients have been raised. We
performed a meta-analysis of 13 trials including 7,964
patients to examine the probabilities of death, nonfatal MI,
angina, and revascularization for up to eight years following
initial CABG or PTCA (7–19). In addition, we performed
analyses to examine relative benefits in subgroups with
isolated proximal left anterior descending (LAD), multives-
sel disease, diabetes, and trials with and without stents in
the initial PTCA strategy.
METHODS
Literature search. We retrieved all articles with a MED-
LINE search from 1966 through 2001, using the Medical
Subject Heading terms “angioplasty, transluminal, percuta-
neous coronary,” “coronary artery bypass,” “randomized
controlled trial,” and “comparative study,” which yielded
116 articles. Additional articles were identified from bibli-
ographies of retrieved articles, including previous meta-
analyses (5,6), personal files, and expert consultation. Since
2001, one additional trial was published and was included
(18).
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Eligible studies for the meta-analysis were limited to
randomized controlled trials comparing the initial strategies
of CABG and PTCA, in patients with multivessel (as
defined by the study investigators) or proximal LAD disease
who were candidates for either procedure. Studies that
utilized stents as one of the initial interventions were
included (15–18). Thirteen randomized trials met the above
criteria for this meta-analysis (10,15–26). We excluded the
Angina With Extremely Serious Operative Mortality Eval-
uation (AWESOME) trial (27) because it enrolled patients
with severe left ventricular dysfunction, ongoing or very
recent MI, or prior heart surgery—clinical characteristics
that would have excluded them from the other 13 trials.
Data abstraction. We captured prespecified data elements
for each trial, including baseline characteristics, inclusion
and exclusion criteria, and outcomes. We examined the
following outcomes: 1) death; 2) cardiac death; 3) nonfatal
MI; 4) subsequent revascularization (CABG or PTCA
following initial strategy); 5) subsequent CABG; 6) subse-
quent PTCA; 7) combined end point of death, MI, or
subsequent revascularization; and 8) angina. In our meta-
analysis, follow-up data from years 2 to 3, 4 to 5, and 6 to
8 were combined where available and reported as three-, five-,
and eight-year end points, respectively. For diabetic patients,
we report outcomes where available at 4 and 6.5 years.
Two independent reviewers (S.N.H., J.A.T.) performed
data extraction from text, tables, and figures, and consensus
was obtained for all data. Discrepancies in data extraction
from text or tables were arbitrated by a third party (J.B.W.
or M.P.W.). Some studies reported revised data for the
same end point in later publications. Hence, we gave
priority to the most recent publication when there was a
discrepancy. Survival curves and histograms were enlarged,
digitally scanned, and then analyzed using CorelDRAW!4
(Corel Corp., Ottawa, Ontario, Canada), using a method
similar to that described by Earle et al. (28).
Agreement between reviewers was analyzed using the
kappa coefficient (kappa  0.936 for agreement within 1%)
using Excel 97 (Microsoft Corp., Redmond, Washington).
We also calculated the intraclass correlation coefficient (29)
(r  0.996; median difference between reviewers  0.2%;
interquartile range 0.1% to 0.6%) using SPSS 10.1 (SPSS
Inc., Chicago, Illinois). Because details regarding dropouts
were not uniformly available, our analysis was unable to
account for censored observations in these analyses (28,30).
Statistical methods. The DerSimonian and Laird (31)
random-effects model was used to obtain a summary esti-
mate of risk difference and a 95% confidence interval (CI)
for each end point. We chose the random-effects model
because of its more conservative summary estimate, incor-
porating variance between and within studies.
All trials were randomized and analyzed based on the
intention-to-treat principle and were reported in peer-
reviewed journals, although the detail to which each study
reported its methodology for randomization, censoring,
handling of crossovers differed slightly. Given the nature of
the treatments, blinding was not possible. Thus, application
of a quality score such as the Jadad scale would likely be
uninformative. In addition, weighting based on quality
scores might introduce bias, and the use of such instruments
is controversial (32). Statistical analysis of binary outcomes
was performed using Meta-Analyst 0.989 (Joseph Lau,
Boston, Massachusetts).
We performed the analysis using different metrics, in-
cluding odds ratio, risk ratio, and risk difference (RD), each
of which produced slightly different estimates of effect size
and heterogeneity. We chose to report RD because it allows
a straightforward calculation of the number needed to treat
(NNT), a useful measure of clinical effectiveness (NNT 
1/RD). In this analysis, a positive RD indicates an advan-
tage for CABG over PTCA. In contrast, a negative RD
means that PTCA is favored over CABG. When the RD is
statistically significant, we report NNT. For example, an
RD of 0.02 would yield an NNT of 50, indicating that
treating 50 patients with CABG would, on average, prevent
one adverse outcome compared to the alternative of treating
the same 50 patients with PTCA. Results using odds and
risk ratios were similar to those reported here using RD and
are available from the authors upon request.
Heterogeneity between studies was evaluated by the
Q-statistic, considered significant for p values 0.10. To
explore the source of heterogeneity, we sorted studies by
event rate in the CABG arm and excluded one or more that
contributed most to the Q-statistic. We performed separate
analyses of prespecified subgroups with different trial char-
acteristics including patients with single- or multivessel
disease and use or nonuse of stents in the initial PTCA
strategy.
Funding sources had no influence on the design, collec-
tion, analysis, interpretation, or approval for publication of
this meta-analysis.
RESULTS
Study selection. Table 1 lists study characteristics for the
13 trials selected for inclusion with a total of 7,964 patients.
Enrollment in these trials was from 1987 to 1999, including
2,764 patients from four trials that used stents in the initial
PTCA strategy. The percentage of screened patients en-
Abbreviations and Acronyms
AWESOME  Angina With Extremely Serious
Operative Mortality Evaluation
CABG  coronary artery bypass graft surgery
LAD  left anterior descending coronary artery
MI  myocardial infarction
NNT  number needed to treat
PTCA  percutaneous transluminal coronary
angioplasty
RD  risk difference
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rolled in the trials ranged from 2% to 12%, except for the
Medicine, Angioplasty, or Surgery Study (MASS) trial,
which enrolled 69% of those screened. All trials included
patients who were eligible for either CABG or PTCA. Ten
studies explicitly excluded patients with prior revasculariza-
tion (Table 1). Argentine Randomized Study: Coronary
Angioplasty with Stenting versus Coronary Bypass Surgery
in Patients with Multivessel Disease (ERACI-II) (16),
permitted prior PTCA (1 year) or left main disease
amenable to stent therapy; analysis with and without this
study did not change the overall results. Results of sensitiv-
ity analyses are available from the authors upon request.
Baseline characteristics were similar between patients
randomized to PTCA and those randomized to CABG.
One notable difference in inclusion criteria was the extent of
anatomic disease present. Three studies (12,15,22) exam-
ined patients with single-vessel (proximal LAD) disease
whereas nine examined patients with multivessel disease
(9,10,16–19,21,24,26,33) and one, the Randomized Inter-
vention Treatment of Angina (RITA) study (20), examined
both types of patients. Two studies specified equivalent
anatomic revascularization (10,19), and four specified equiv-
alent functional revascularization (16,21,23,24). Most pa-
tients were men, with a high prevalence of hypertension,
smoking, and angina. The proportion of patients with
diabetes varied from 6% to 25% (Table 1).
Death, cardiac death, and nonfatal MI (all studies). We
found no statistically significant risk difference for death or
cardiac death between the two revascularization strategies,
except at year 5 when there was a 1.9% to 2.0% RD favoring
CABG over PTCA (CIs 0.33% to 3.4% for death and
0.29% to 3.7% for cardiac death, p  0.02) (Fig. 1A),
corresponding to NNTs of 53 for death and 51 for cardiac
death favoring CABG. Although the magnitude of the
difference in eight-year all-cause mortality was similar, fewer
studies were available, and the results were not statistically
significant. When compared with each other, neither CABG
nor PTCA reduced nonfatal MI (Table 2).
Subsequent revascularization, combined end points, or
angina (all studies). Risk of additional revascularization
procedure (PTCA or CABG) was higher following PTCA
at all time points (RDs 24% to 38%, p  0.001), with most
of the difference occurring in the first year. For the com-
bined end point of death, MI, or any additional revascular-
Figure 1. Risk difference for all-cause mortality for years 1, 3, 5, and 8 post-initial revascularization. All trials (A) and multivessel coronary artery disease
(B). The lines represent 95% confidence intervals. Event rates for the coronary bypass arm at one, three, five, and eight years for all trials (A) were 3.0%,
4.7%, 7.1%, and 13.7%; for multivessel trials (B) were 3.4%, 5.3%, 8.9%, and 15.8%. CABG coronary artery bypass graft surgery; PTCA percutaneous
transluminal coronary angioplasty.
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Table 1. Demographic Data from Included Studies
RITA ERACI Lausanne GABI EAST CABRI MASS* BARI Toulouse SIMA† ERACI II† ARTS† SoS†
Total patients 1011 127 134 359 392 1054 142 1829 152 121 450 1205 988
PTCA, n 510 63 68 182 198 541 72 915 76 62 225 600 488
CABG, n 501 64 66 177 194 513 70 914 76 59 225 605 500
Age (mean) (yrs) 57 57 56  75 62 60 56 61 67 59 62 61 61
PTCA n/a 59 57 n/a 62 60 54 62 66 59 62 61 61
CABG n/a 55 54 n/a 61 60 58 61 68 60 61 61 62
Male, n (%)
PTCA 422 (83) 51 (81) 54 (79) 144 (79) 148 (75) 421 (78) 58 (81) 666 (73) 55 (72) 47 (76) 174 (77) 462 (77) 390 (80)
CABG 394 (79) 57 (89) 53 (80) 142 (80) 141 (73) 399 (78) 58 (83) 674 (74) 62 (82) 49 (83) 183 (81) 460 (76) 392 (78)
DM, n (%)
PTCA 33 (6) 7 (11) 8 (12) 18 (10) 49 (25) 64 (12) 15 (21) 218 (24) 11 (14) 7 (11) 39 (17) 114 (19) 68 (14)
CABG 29 (6) 7 (11) 8 (12) 27 (15) 41 (21) 60 (12) 18 (26) 226 (25) 9 (12) 8 (14) 39 (17) 97 (16) 74 (15)
HTN, n (%)
PTCA n/a 33 (52) 31 (46) 76 (42) 106 (54) 190 (35) 34 (47) 449 (49) 31 (41) 28 (45) 160 (71) 270 (45) 212 (43)
CABG n/a 37 (58) 27 (41) 69 (39) 100 (52) 188 (37) 30 (43) 447 (49) 33 (43) 28 (47) 159 (70) 272 (45) 235 (47)
Smokers, n (%)
PTCA n/a 39 (62) 40 (59) 127 (70) 38 (19) 79 (15) 36 (50) 238 (26) 39 (51) 35 (56) 122 (54) 168 (28) 77 (16)
CABG n/a 45 (70) 34 (52) 119 (67) 41 (21) 66 (13) 37 (53) 219 (24) 41 (54) 30 (51) 111 (50) 157 (26) 72 (14)
Prior MI, n (%)
PTCA 217 (43) 32 (51) n/a 84 (46) 81 (41) 224 (41) n/a 488 (53) 28 (37) 1 (2) 64 (28) 264 (44) 214 (44)
CABG 210 (42) 31 (48) n/a 83 (47) 79 (41) 215 (42) n/a 499 (55) 29 (38) 1 (2) 62 (28) 254 (42) 234 (47)
CCS class 0–2, n (%)
PTCA 220 (43) n/a 5 (7) n/a 43 (22) 215 (40) n/a 176 (19) n/a 32 (52) n/a n/a n/a
CABG 194 (39) n/a 9 (14) n/a 34 (18) 175 (34) n/a 172 (19) n/a 30 (51) n/a n/a n/a
CCS class 3–4, n (%)
PTCA 289 (57) n/a 54 (79) n/a 147 (74) 245 (45) n/a 160 (17) 35 (46) 30 (48) n/a n/a 210 (43)
CABG 304 (61) n/a 51 (77) n/a 155 (80) 254 (50) n/a 140 (15) 45 (59) 29 (49) n/a n/a 241 (48)
Unstable angina, n (%)
PTCA 282 (55) 48 (76) 8 (12) 24 (13) n/a 74 (14) n/a 563 (62) n/a n/a 207 (92) 222 (37) n/a
CABG 275 (55) 57 (89) 5 (8) 27 (15) n/a 79 (15) n/a 585 (64) n/a n/a 204 (91) 212 (35) n/a
Mean cholesterol
PTCA n/a n/a n/a n/a 218 237 213 217 n/a 217 n/a n/a n/a
CABG n/a n/a n/a n/a 224 223 230 220 n/a 220 n/a n/a n/a
Dyslipidemia, n (%)
PTCA n/a 35 (56) n/a 109 (60) n/a n/a n/a 412 (45) n/a 38 (61) 141 (62) 348 (58) 258 (53)
CABG n/a 39 (61) n/a 108 (61) n/a n/a n/a 393 (43) n/a 32 (54) 135 (60) 135 (58) 251 (50)
Mean EF (%)
PTCA n/a 59 n/a n/a 61 63 77 57 n/a 67 n/a 61 57
CABG n/a 62 n/a n/a 62 63 74 58 n/a 67 n/a 60 57
3VD, n (%)
PTCA 63 (12) 27 (43) 0 (0) 27 (15) 79 (40) 216 (40) n/a 378 (41) 21 (28) n/a 123 (55) 180 (30) 183 (38)
CABG 61 (12) 30 (47) 0 (0) 39 (22) 77 (40) 222 (43) n/a 376 (41) 23 (30) n/a 130 (58) 200 (33) 236 (47)
2VD, n (%)
PTCA 213 (42) 36 (57) 0 (0) 155 (85) 119 (60) 316 (58) n/a 537 (59) 55 (72) n/a 90 (40) 408 (68) 303 (62)
CABG 218 (44) 34 (53) 0 (0) 138 (78) 117 (60) 288 (56) n/a 538 (59) 53 (70) n/a 86 (38) 405 (67) 262 (52)
Continued on next page
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ization, the risk was always higher in the PTCA group
(RDs 26% to 31%, p  0.001). After one and three years,
patients treated with CABG had a lower risk of angina than
those receiving PTCA with a risk difference of 10% (p 
0.001). After five years, this difference decreased to 5.3% and
was no longer statistically significant (Table 2).
Trials with and without stents. Since the early trials of
CABG versus PTCA, stents have become an important
adjunct to balloon angioplasty. To assess this advance in
technology, we performed subgroup analyses of trials with
and without stents in the initial PTCA arm where data were
available from at least two trials. For all-cause mortality,
there was a trend favoring CABG over PTCA in pre-stent
trials at three years (Table 3) (RD 1.1%, CI 0.1 to 2.3, p
 0.08) that was no longer present in trials with stents
(Table 4). This trend favoring CABG disappeared despite a
reduction in mortality in the CABG arm from 5.2% in trials
without stents to 3.5% in the more recent trials with stents.
At three years, PTCA with stent provided a statistically
significant reduction in nonfatal MI compared to CABG
(RD 2.9%, CI 5.1 to 0.6%, p  0.01) (Table 4).
Although subsequent revascularization was still more fre-
quent after PTCA with stent than after CABG, the risk
difference for revascularization in trials with stents was
about half that observed in trials without stents (Fig. 2). In
trials without stents, however, neither CABG nor PTCA
provided a significant advantage for preventing all-cause
mortality or for preventing nonfatal MI at one or three years
(Table 3).
Trials with multi- or single-vessel (proximal LAD)
disease. We also performed meta-analyses of trials involv-
ing only multivessel or single-vessel (proximal LAD) dis-
ease. For patients with multivessel disease, risk of death was
lower in the CABG-treated patients at five years (RD 2.3%,
CI 0.29% to 4.3%, p  0.025) and at eight years (RD 3.4%,
CI 0.32% to 6.4%, p  0.03) (Fig. 1B). Similarly, CABG
lowered cardiac death at year 5 (RD 2.4%, CI 0.44% to
4.3%, p  0.016). However, PTCA had a lower likelihood
of nonfatal MI than CABG at three years (RD 3.3%, CI
5.5 to 1.1%, p  0.004).
For those with single-vessel proximal LAD disease, the
risk of death was lower in CABG-treated patients at year 5
(RD 5.6%, CI 0.19% to 11%, p  0.042), but there was no
statistically significant difference in all-cause mortality at
year 3. Neither CABG nor PTCA was significantly favored
for preventing cardiac death or nonfatal MI at years 3 or 5
(Tables 5 and 6). For single-vessel trials, data were insuffi-
cient for analysis at years 1 and 8.
Trials reporting outcomes in diabetic patients. We com-
bined survival data from the four trials reporting on sub-
groups of patients with diabetes mellitus (9,20,34,35). At
four years, we combined data from the Emory Angioplasty
versus Surgery Trial (EAST), Coronary Angioplasty versus
Bypass Revascularization Investigation (CABRI), and By-
pass Angioplasty Revascularization Investigation (BARI)
studies, and at 6.5 years, from the RITA, EAST, and BARITa
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studies. At 4 years, CABG was favored over PTCA for
preventing all-cause death (RD 8.6%, CI 2.2% to 15%, p 
0.01), but after 6.5 years, CABG was no longer significantly
favored (RD 3.9%, CI 17% to 25%, p  0.71). For
nondiabetic patients, there was no significant difference in
survival at 4 or 6.5 years (Fig. 3, Table 7).
Analysis of heterogeneity. Heterogeneity was significant
for survival in trials with stents and in the diabetic subgroup.
Removing the Stent or Surgery (SoS) study (18) reduced
heterogeneity to nonsignificant levels with a survival advan-
tage for PTCA with stent at three years (RD 3.5%, CI
6.8% to 0.2%, p  0.04). In the SoS study, there were
eight cancer deaths in the stent arm and one in the CABG
arm, which may explain the heterogeneity. Similarly, re-
moving the RITA study from the diabetic data reduced
heterogeneity to nonsignificant levels and resulted in a
significant advantage for CABG at 6.5 years (RD 15.5%, CI
7% to 24%, p  0.001). Notably, the RITA study had more
deaths in the CABG than the PTCA arm among diabetic
patients and was the only trial of these four that included
diet-controlled diabetic patients in reporting this subgroup,
which may explain the heterogeneity.
DISCUSSION
Our meta-analysis included 13 trials involving 7,964 eligible
patients with CAD randomized to CABG or PTCA,
followed for up to eight years. In the overall analysis, neither
strategy provided a statistically significant survival advantage
at one, three, or eight years. At five years, there was a
statistically significant 1.9% RD advantage favoring CABG
(Fig. 1A). Subgroup analysis of multivessel trials showed a
similar survival advantage for CABG at years 5 and 8 (Fig.
Table 2. All Trials
Outcome
Pts
(Trials)
Heterogeneity
(p Value)
RD, %
(95% CI) p Value NNT References
Freedom from
Death
1 yr 7,709 (11) 13.6 (NS) 0.34 (0.54 to 1.2) 0.45 (8–10,16–19,21,24–26)
3 yrs 6,400 (11) 15.6 (NS) 0.86 (0.53 to 2.3) 0.23 (8–10,13–16,18,22,25,26)
5 yrs 4,714 (7) 3.7 (NS) 1.9 (0.33 to 3.4) 0.02 53 (8–13,26)
8 yrs 3,384 (4) 3.6 (NS) 1.5 (1.2 to 4.2) 0.28 (7–10)
Cardiac death
1 yr 780 (4) 2.6 (NS) 0.73 (1.3 to 2.7) 0.47 (10,19,21,25)
3 yrs 3,067 (8) 2.9 (NS) 0.21 (0.72 to 1.14) 0.65 (10,15,18,20–23,25)
5 yrs 2,649 (5) 1.5 (NS) 2.0 (0.29 to 3.7) 0.02 51 (9–12,33)
8 yrs 1,403 (2) 0.4 (NS) 0.34 (2.5 to 1.8) 0.76 (8,9)
Nonfatal MI
1 yr 4,325 (7) 11.7 (0.1) 0.76 (2.6 to 1.1) 0.43 (12,16–19,21,24)
3 yrs 3,365 (8) 13.9 (0.1) 0.48 (3.0 to 2.0) 0.71 (9,14–16,18,20,22,23,25)
5 yrs 2,257 (4) 4.5 (NS) 1.4 (2.5 to 5.3) 0.48 (10–12,26)
Subsequent revascularization
(CABG or PTCA)
1 yr 7,709 (11) 294 (0.001) 24 (16 to 32)  0.001 4 (8–10,12,16–19,21,24,26)
3 yrs 6,258 (10) 170 (0.001) 28 (20 to 36)  0.001 4 (8–10,13–16,18,22,26)
5 yrs 4,572 (6) 27 (0.001) 37 (31 to 44)  0.001 3 (8–11,13,26)
8 yrs 3,384 (4) 18 (0.001) 38 (30 to 46)  0.001 3 (7–10)
Subsequent CABG
1 yr 7,259 (10) 183 (0.001) 13 (8.0 to 18)  0.001 8 (8–10,12,17–19,21,24,26)
3 yrs 4,896 (9) 100 (0.001) 17 (11 to 23)  0.001 6 (8–10,12,13,15,18,21,22,26)
5 yrs 3,660 (6) 27 (0.001) 22 (16 to 27)  0.001 5 (8–12,26)
8 yrs 3,384 (4) 22 (0.001) 26 (19 to 33)  0.001 4 (7–10)
Subsequent PTCA
1 yr 7,259 (10) 124 (0.001) 14 (9.1 to 19)  0.001 6 (8–10,12,17–19,21,24,26)
3 yrs 4,896 (9) 81 (0.001) 16 (9.9 to 23)  0.001 6 (8–10,12,13,15,18,21,22,26)
5 yrs 3,660 (6) 32 (0.001) 23 (16 to 30)  0.001 4 (8–12,26)
8 yrs 3,384 (4) 16 (0.005) 20 (12 to 27)  0.001 5 (7–10)
Death, MI, or revascularization
1 yr 1,280 (3) 3.6 (NS) 26 (18 to 33)  0.001 4 (12,20,21)
3 yrs 1,535 (5) 1.5 (NS) 26 (22 to 30)  0.001 4 (14,15,20,22,25)
5 yrs 276 (2) 0.02 (NS) 31 (21 to 41)  0.001 3 (11,12)
Angina
1 yr 6,707 (8) 17 (0.02) 11 (7.5 to 14)  0.001 9 (14,17–20,22,24,35)
3 yrs 5,260 (9) 24 (0.005) 9.0 (5.0 to 13)  0.001 11 (13,15,16,20–23,25,35)
5 yrs 4,322 (6) 26 (0.001) 5.3 (0.82 to 11) 0.09 (8,10–13,35)
Risk difference (RD) event rate for percutaneous transluminal coronary angioplasty (PTCA) group minus the event rate for coronary artery bypass graft surgery (CABG) group;
NNT  1/RD: number of patients needed to treat with CABG to prevent one adverse outcome in the same number of patients treated with PTCA, rounded to nearest integer
and only reported if 95% confidence interval (CI) for RD does not cross zero; when RD is negative, a negative NNT is the number of patients needed to treat with PTCA to
prevent one adverse outcome in the same number of patients treated with CABG; NS  nonsignificant p value. *8-year data not available.
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1B). The long-term survival advantage for CABG is con-
sistent with observational studies suggesting greater benefit
from CABG over PTCA for patients with CAD (36,37).
However, it must be noted that all data at five and eight
years are from earlier studies that did not employ stents in
the initial revascularization procedure. The trend favoring
CABG for survival at three years in pre-stent trials was no
longer present in the stent era, despite a decrease in absolute
mortality following CABG. Whether the introduction of
stents and improvements in CABG will affect long-term
results remains to be seen.
Our analysis of the diabetic subgroup reflects heteroge-
neity in outcomes reported in the literature. Coronary artery
bypass graft surgery provided a statistically significant sur-
Table 3. Trials Without Stents
Outcome
Pts
(Trials)
Heterogeneity
(p Value)
RD, %
(95% CI) p Value NNT References
Freedom from
Death
1 yr 5,066 (8) 3.9 (NS) 0.52 (0.37 to 1.4) 0.26 (8–10,19,21,24–26)
3 yrs 4,841 (8) 4.9 (NS) 1.1 (0.13 to 2.3) 0.08 (8–10,13,14,22,25,26)
Cardiac death
3 yrs 1,958 (6) 0.6 (NS) 0.4 (1.7 to 0.85) 0.51 (10,20–23,25)
Nonfatal MI
1 yr 1,682 (4) 3.5 (NS) 0.22 (2.0 to 2.0) 0.84 (12,19,21,24)
3 yrs 1,806 (5) 5.6 (NS) 1.2 (1.8 to 4.2) 0.42 (9,14,20,22,25)
Subsequent revascularization
(CABG or PTCA)
1 yr 5,066 (8) 239 (0.001) 27 (17 to 38)  0.001 4 (8–10,12,19,21,24,26)
3 yrs 4,699 (7) 31 (0.001) 34 (28 to 40)  0.001 3 (8–10,13,14,22,26)
Subsequent CABG
1 yr 5,066 (8) 140 (0.001) 15 (8.0 to 21)  0.001 7 (8–10,12,19,21,24,26)
3 yrs 3,787 (7) 23 (0.001) 20 (15 to 24)  0.001 5 (8–10,12,21,22,26)
Subsequent PTCA
1 yr 5,066 (8) 109 (0.001) 15 (9.0 to 22)  0.001 7 (8–10,12,19,21,24,26)
3 yrs 3,787 (7) 50 (0.001) 17 (10 to 24)  0.001 6 (8–10,12,21,22,26)
Death, MI, or revascularization
3 yrs 1,414 (4) 1.3 (NS) 26 (22 to 31)  0.001 4 (14,20,22,25)
Angina
1 yr 4,514 (6) 16 (0.01) 10 (5 to 15)  0.001 10 (14,19,20,22,24,35)
3 yrs 4,689 (7) 24 (0.001) 9.7 (4.6 to 15)  0.001 10 (13,20–23,25,35)
Note: Year 5–8 data identical to all trial data as in Table 2. Table 2 footnote applies to Tables 3 through 7.
Table 4. Trials With Stents
Outcome
Pts
(Trials)
Heterogeneity
(p Value)
RD, %
(95% CI) p Value NNT References
Freedom from
Death
1 yr 2,643 (3) 9.6 (0.01) 0.6 (3.4 to 2.2) 0.67 (16–18)
3 yrs 1,559 (3) 10.7 (0.01) 0.82 (5.9 to 4.3) 0.75 (15,16,18)
Cardiac death
3 yrs 1,109 (2) 0.21 (NS) 0.94 (0.42 to 2.3) 0.17 (15,18)
Non-fatal MI
1 yr 2,643 (3) 6.9 (0.05) 1.5 (4.7 to 1.7) 0.35 (16–18)
3 yrs 1,559 (3) 1.8 (NS) 2.9 (5.1 to 0.6) 0.01 35 (15,16,18)
Subsequent revascularization
(CABG or PTCA)
1 yr 2,643 (3) 2.9 (NS) 15 (12 to 18)  0.001 7 (16–18)
3 yrs 1,559 (3) 3.8 (NS) 15 (10 to 20)  0.001 7 (15,16,18)
Subsequent CABG
1 yr 2,193 (2) 0.2 (NS) 6.3 (4.7 to 7.9)  0.001 16 (17,18)
3 yrs 1,109 (2) 0.5 (NS) 8.3 (5.8 to 11)  0.001 12 (15,18)
Subsequent PTCA
1 yr 2,193 (2) 3.4 (0.1) 10 (6.0 to 14)  0.001 10 (17,18)
3 yrs 1,109 (2) 3.3 (0.1) 12 (2.6 to 21) 0.01 8 (15,18)
Angina
1 yr 2,193 (2) 0.4 (NS) 11.4 (8.1 to 15)  0.001 9 (17,18)
3 yrs 571 (2) 0 (NS) 7.7 (2.7 to 13) 0.0025 13 (15,16)
Table 2 footnote applies to Tables 3 through 7.
1299JACC Vol. 41, No. 8, 2003 Hoffman et al.
April 16, 2003:1293–304 A Meta-Analysis Comparing CABG With PTCA
Figure 2. Risk difference for subsequent revascularization comparing coronary artery bypass graft surgery (CABG) to percutaneous transluminal coronary
angioplasty (PTCA) ( stents) for years 1 and 3. The lines represent 95% confidence intervals. For trials with stents, numbers of patients and trials are
adjacent to data at one and three years. Year 5 and 8 data were available only for CABG versus PTCA without stent.
Table 5. Trials of Single-Vessel (Proximal LAD) Disease Only
Outcome
Pts
(Trials)
Heterogeneity
(p Value)
RD, %
(95% CI) p Value NNT References
Freedom from
Death
3 yrs 397 (3) 1.4 (NS) 0.23 (2.6 to 3.0) 0.87 (15,22,25)
5 yrs 276 (2) 0 (NS) 5.6 (0.19 to 11) 0.042 18 (11,12)
Cardiac death
3 yrs 397 (3) 0.32 (NS) 0.6 (3.0 to 1.8) 0.65 (15,22,25)
5 yrs 276 (2) 0.48 (NS) 0.73 (2.8 to 4.2) 0.68 (11,12)
Nonfatal MI
3 yrs 397 (3) 2.3 (NS) 2.8 (1.2 to 6.7) 0.17 (15,22,25)
5 yrs 276 (2) 2.1 (NS) 5.0 (3.6 to 14) 0.25 (11,12)
Subsequent revascularization
(CABG or PTCA)
3 yrs 255 (2) 0.22 (NS) 22 (14 to 30)  0.001 4 (15,22)
Subsequent CABG
3 yrs 397 (3) 0.11 (NS) 12 (7.6 to 17)  0.001 8 (12,15,22)
5 yrs 276 (2) 1.1 (NS) 15 (8.9 to 22)  0.001 7 (11,12)
Subsequent PTCA
3 yrs 397 (3) 9.4 (0.01) 18 (5.5 to 30)  0.005 6 (12,15,22)
5 yrs 276 (2) 0.26 (NS) 27 (19 to 36)  0.001 4 (11,12)
Death, MI, or revascularization
3 yrs 397 (3) 0.64 (NS) 24 (17 to 31)  0.001 4 (12,15,22)
5 yrs 276 (2) 0.02 (NS) 31 (21 to 41)  0.001 3 (11,12)
Angina
3 yrs 397 (3) 1.6 (NS) 12 (6.2 to 18)  0.001 8 (12,15,22)
5 yrs 276 (2) 0.77 (NS) 2.4 (8.5 to 13) 0.66 (11,12)
Table 2 footnote applies to Tables 3 through 7.
Figure 3. Risk difference for all-cause mortality for years 4 and 6.5 post-initial revascularization comparing coronary artery bypass graft surgery (CABG)
to percutaneous transluminal coronary angioplasty (PTCA) for diabetic and non-diabetic patients. The lines represent 95% confidence interval.
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vival advantage for diabetics over PTCA at 4 years but not
at 6.5 years (Fig. 3), unless the RITA study is excluded.
This advantage for CABG was not seen among nondiabetic
patients, suggesting survival benefit only in diabetics. Reg-
istry data have also shown mixed results: some have suggested
a survival advantage for CABG in diabetics (38) whereas
others have not (39). Because the published diabetic random-
ized controlled trials data are all post-hoc analyses and not
prespecified subgroups, they are subject to bias.
Angina and revascularization rates were higher following
PTCA in the overall analysis and in all subgroups. For all
trials, there was a 24% RD for repeat revascularization
favoring CABG at one year increasing to 38% by eight years
despite the expected need for revascularization in CABG
patients due to failure of bypass grafts. With stents, how-
ever, the one- and three-year revascularization RD was
reduced by one-half to 15%, perhaps because of reduced
incidence of coronary restenosis (40). Drug-eluting stents
may further reduce restenosis (41).
These revascularization results need to be interpreted
with some caution because of the degree of heterogeneity
found in reported outcomes. The decision for repeat revas-
Table 6. Trials of Multivessel Disease
Outcome
Pts
(Trials)
Heterogeneity
(p Value)
RD, %
(95% CI) p Value NNT References
Freedom from
Death
1 yr 6,556 (9) 13 (NS) 0.12 (1.1 to 1.3) 0.84 (9,10,16–19,21,24,26)
3 yrs 4,992 (7) 11 (0.1) 1.3 (0.6 to 3.2) 0.19 (9,10,16,18,21,24,26)
5 yrs 3,427 (4) 0.2 (NS) 2.3 (0.29 to 4.3) 0.025 44 (9,10,24,26)
8 yrs 2,373 (3) 0.02 (NS) 3.4 (0.32 to 6.4) 0.030 30 (7,9,10)
Cardiac death
1 yr 638 (3) 2.4 (NS) 0.69 (2.1 to 3.5) 0.63 (10,19,21)
3 yrs 1,659 (4) 0.7 (NS) 0.84 (0.45 to 2.1) 0.20 (10,18,21,23)
5 yrs 2,373 (3) 0.4 (NS) 2.4 (0.44 to 4.3) 0.016 42 (9,10,33)
Nonfatal MI
1 yr 4,183 (6) 11.7 (0.05) 0.92 (3.1 to 1.3) 0.41 (16–19,21,24)
3 yrs 1,957 (4) 0.9 (NS) 3.3 (5.5 to 1.1) 0.004 30 (14,16,18,23)
5 yrs 1,981 (2) 0.2 (NS) 0.58 (3.3 to 2.2) 0.68 (10,26)
Subsequent revascularization
(CABG or PTCA)
1 yr 6,556 (9) 164 (0.001) 26 (18 to 34)  0.001 4 (9,10,16–19,21,24,26)
3 yrs 4,992 (7) 161 (0.001) 28 (17 to 40)  0.001 4 (9,10,13,14,16,18,26)
5 yrs 3,427 (4) 23 (0.001) 38 (30 to 47)  0.001 3 (9,10,13,26)
8 yrs 2,373 (3) 17 (0.001) 36 (22 to 50)  0.001 3 (7–10)
Subsequent CABG
1 yr 6,106 (8) 114 (0.001) 14 (9.2 to 20)  0.001 7 (9,10,17–19,21,24,26)
3 yrs 3,488 (5) 92 (0.001) 19 (9.1 to 29)  0.001 5 (9,10,18,21,26)
5 yrs 2,373 (3) 11 (0.005) 24 (17 to 32)  0.001 4 (9,10,26)
8 yrs 2,373 (3) 17 (0.001) 26 (16 to 36)  0.001 4 (7,9,10)
Subsequent PTCA
1 yr 6,106 (8) 72 (0.001) 16 (11 to 21)  0.001 6 (9,10,17–19,21,24,26)
3 yrs 3,488 (5) 70 (0.001) 16 (5.2 to 26) 0.0033 6 (9,10,18,21,26)
5 yrs 2,373 (3) 14 (0.001) 23 (12 to 34)  0.001 4 (9–11,26)
8 yrs 2,373 (3) 9.3 (0.01) 21 (11 to 30)  0.001 5 (7,9,10)
Angina
1 yr 5,562 (6) 17 (0.01) 11 (6.4 to 15)  0.001 9 (14,17,19,24,35)
3 yrs 3,852 (5) 19 (0.001) 7.7 (1.9 to 13) 0.009 13 (13,16,21,23,35)
5 yrs 3,035 (3) 16 (0.005) 4.4 (3.9 to 13) 0.30 (10,13,35)
Table 2 footnote applies to Tables 3 through 7.
Table 7. Trials of Diabetics and Nondiabetics
Outcome
Pts
(Trials)
Heterogeneity
(p Value)
RD, %
(95% CI) p Value NNT References
Freedom from
Death (diabetic patients)
4 yrs 537 (3) 1.3 (NS) 8.6 (2.2 to 15)  0.01 12 (9,34,35)
6.5 yrs 474 (3) 11.4 (0.01) 3.9 (17 to 25) 0.71 (8,9,35)
Death (nondiabetic patients)
4 yrs 2,738 (3) 1.6 (NS) 1.1 (0.83 to 3.1) 0.26 (9,34,35)
6.5 yrs 2,758 (3) 0.29 (NS) 0.09 (2.2 to 2.3) 0.94 (8,9,35)
Table 2 footnote applies to Tables 3 through 7.
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cularization was not specified by the individual study pro-
tocols but was made by patients and their physicians and,
therefore, was susceptible to differences in local practice
patterns. Nonetheless, higher revascularization rates with
PTCA might be explained in part by less complete revas-
cularization with the initial PTCA (21,42), the lower
likelihood of successful PTCA with bypass grafts in the
CABG arm, the higher likelihood of operative mortality for
repeat CABG, and the lower risk for angina with CABG.
Additional sources of heterogeneity include variable defini-
tions of outcomes such as postprocedure MI, the incidence
of which may be biased by differences in surveillance and
ascertainment.
There are several possible limitations to the present study.
As in any meta-analysis, publication bias is always a concern
(43). However, it is unlikely that a major randomized
controlled trial escaped our search strategy and was also
unknown to local experts. Our analysis only considered
published rather than individual patient data; the latter
would have permitted explicit examination of censored
observations. To account in part for censoring, we elected to
combine data for outcomes at specific time points. Because
not all trials published the outcomes at the time points of
interest, different studies contributed to the summary sta-
tistic at each time point.
For example, seven trials contributed to the overall
analysis for five-year survival, but only four trials contributed
at eight years (Fig. 1A, Table 2). While the point estimates
for risk difference at five and eight years were similar (1.9%
and 1.5%, respectively), the confidence interval was wider at
eight years and the difference was no longer statistically
significant, possibly due to reduced power. A new trial
separate from this meta-analysis with 80% power to detect
a 1.5% mortality difference at eight years would require
about 8,700 patients. Note that such calculations of power
to help explain a nonsignificant result after a trial has been
completed, that is, “post-hoc power” analysis, may introduce
problems with interpretation (44). A true reduction of the
benefit from CABG or variation in included trials might
also explain the lack of a significant survival advantage for
CABG at eight years.
Multiple statistical comparisons were done over time for
each clinical end point, raising the likelihood of seeing
differences through chance alone. The use of Bonferroni’s
method for multiple comparisons in meta-analysis would be
a conservative statistical correction but is controversial (29).
When applied to our meta-analysis, neither PTCA nor
CABG provided statistically significant benefit for the end
points of death or cardiac death, except for cardiac death at
five years for patients with multivessel disease, which
continued to favor CABG.
Patients included in these trials are a carefully selected
subgroup of coronary patients, typically 2% to 12% of those
screened, so our results may not be generalizable to patients
seen by community physicians. These results would appear
to be most applicable to male smokers in their early 60s who
are at low risk for cardiac death. Many sicker patients, such
as those with heart failure, were ineligible for these trials.
Recent trials, such as AWESOME (27), that include
patients at high risk of cardiac death are addressing some of
these questions.
Where comparable, the results of our overall meta-
analysis showed no major differences from prior meta-
analyses (5,6), for one- to three-year outcomes. Patients
who underwent CABG had significantly fewer repeat re-
vascularizations and less angina, and neither strategy had a
clear advantage for preventing death or nonfatal MI at one
to three years.
How then does one decide between CABG and PTCA?
Certainly some patients may prefer having an initial PTCA
to avoid the morbidity and short-term mortality incurred by
having cardiac surgery (6,45–47). Other patients may prefer
the lower risk for subsequent angina and the lower need for
repeat revascularization after CABG. Still other patients,
such as those with multivessel disease, may place greater
emphasis on the potential long-term survival benefit with
CABG. Although our analysis showed no significant sur-
vival advantage for PTCA with stent over CABG at one
and three years, further studies and longer term data are
needed, as only 35% of PTCA patients had stents in the
initial revascularization.
Health technology assessment needs to be an ongoing
process so physicians can be informed of the most efficacious
technologies for providing health care (48). Our analysis
contributes to this process by providing an assessment of
currently available long-term data and recent trials, some of
which include stents. Even though the technology has
advanced and current treatments differ from earlier studies,
our analysis can provide a benchmark against which future
studies can be compared.
Overall, selected patients with coronary disease had a
small survival advantage with CABG over PTCA at five
years of follow-up, none of whom underwent initial stent-
ing. The addition of stents and newer adjunctive therapies
may improve outcomes from percutaneous interventions
relative to CABG, but long-term data are not yet available.
Repeat revascularization and angina were consistently lower
with CABG compared to PTCA, although stents reduced
the difference in repeat revascularization. Some patients may
prefer to avoid the risk of surgical morbidity and mortality
despite these potential long-term benefits. The decision to
recommend CABG or PTCA will be guided by the results
of randomized trials, technical improvements, local exper-
tise, patient preferences, and periodic technology assess-
ments, such as the meta-analysis presented here.
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